Anzeige
❌
Mehr »
Samstag, 21.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
RL

WKN: A3DPNV | ISIN: CA76206T1084 | Ticker: 4YX0
Frankfurt
20.11.26 | 08:13
0,004 Euro
-11,11 % -0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
RHELION LIFE SCIENCES CORP Chart 1 Jahr
5-Tage-Chart
RHELION LIFE SCIENCES CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0080,01413:04

Aktuelle News zur RHELION LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrRhelion Life Sciences Corp: Rhelion's Filament issued new U.S. patent for PEX0103
RHELION LIFE SCIENCES Aktie jetzt für 0€ handeln
DoRhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate442A new United States patent, "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation," has been issued by the United States Patent and Trademark Office, adding to the intellectual...
► Artikel lesen
DiRhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being486Filament has shipped PEX010 to the University of California, San Francisco (UCSF) for OAD1, a Phase 1 trial of psilocybin in healthy older adults with low well-being.Toronto, Ontario--(Newsfile Corp....
► Artikel lesen
10.11.Rhelion Life Sciences Corp: Rhelion's Filament ships PEX010 for Sleepy study2
09.11.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to King's College London453Filament has shipped PEX010 to King's College London for SLEEPY, a feasibility study of giving psilocybin just before sleep.Toronto, Ontario--(Newsfile Corp. - November 9, 2026) - Rhelion Life Sciences...
► Artikel lesen
03.11.Rhelion Life Sciences Corp: Rhelion's Filament Health ships PEX010 to USC6
03.11.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial562Filament has shipped PEX010 to the Keck School of Medicine of USC for the first order under the expanded supply agreement for its Mindfulness Assisted Psychedelic Therapy trial.Toronto, Ontario--(Newsfile...
► Artikel lesen
02.11.Rhelion Life Sciences Corp: Rhelion Life Sciences completes IBEX011 extraction6
02.11.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing393Filament has completed a new extraction of IBEX011The Company expects Filament to begin stability testing on the new extract shortlyToronto, Ontario--(Newsfile Corp. - November 2, 2026) - Rhelion Life...
► Artikel lesen
28.10.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder364Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.Toronto, Ontario--(Newsfile Corp. - October...
► Artikel lesen
16.10.Rhelion Life Sciences Corp: Rhelion's Filament enters supply deal with Epsylon6
16.10.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression660Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.Filament...
► Artikel lesen
14.10.Rhelion Life Sciences Corp: Rhelion reappoints Carhart-Harris as scientific adviser9
14.10.Rhelion Life Sciences Corp.: Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor709Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.Toronto, Ontario--(Newsfile Corp. - October...
► Artikel lesen
09.10.Rhelion Life Sciences Corp: Rhelion Life to supply psilocybin to UCSF meth trial2
08.10.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV619Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition...
► Artikel lesen
29.09.Rhelion Life Sciences Corp: Rhelion unit ships PEX010 for Calgary PTSD trial9
29.09.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence405Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.Toronto...
► Artikel lesen
25.09.Rhelion Life Sciences Corp: Rhelion unit expands PEX010 supply for Italian trial6
25.09.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy624Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support...
► Artikel lesen
1 2 3 4 5 Weiter >>
92 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1